{
    "clinical_study": {
        "@rank": "1373", 
        "arm_group": {
            "arm_group_label": "Resistant Hypertension", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The RENABLATE study is a prospective, multi-center, non-randomized feasibility study to\n      evaluate the safety and effectiveness of the investigational Celsius\u00ae ThermoCool\u00ae RD\n      Multi-electrode Ablation Catheter and integrated ablation system to treat resistant\n      hypertension."
        }, 
        "brief_title": "RENABLATE Feasibility - EC12-02", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Denervation", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is > 18 and < 85 years old.\n\n          2. Individual has a systolic blood pressure \u2265 160 mmHg (\u2265 150 mmHg for type 2 diabetics)\n             based on an average of 3 office blood pressure readings.\n\n          3. Individual is adhering to a stable drug regimen of at least 3 different classes of\n             anti-hypertensive medications, including a diuretic (with no changes for a minimum of\n             2 weeks prior to enrollment) at optimal dose and is expected to be maintained for at\n             least 6 months.\n\n          4. Individual agrees to have all study procedures performed, and is competent and\n             willing to provide written, informed consent to participate in this study.\n\n        Exclusion Criteria:\n\n          1. Subjects with known/diagnosed secondary hypertension.\n\n          2. Subject has 'White Coat' hypertension defined as 24 hour daytime systolic blood\n             pressure <135 mm Hg as evaluated at Baseline visit.\n\n          3. Subject has aorto-ilio-femoral artery anatomy not suitable for treatment with the\n             investigational Celsius\u00ae ThermoCool\u00ae RD Multi-electrode Ablation Catheter.\n\n          4. Subject has main renal arteries that are < 20 mm in length or < 4 mm in diameter.\n\n          5. Subject has multiple main renal arteries in either kidney.\n\n          6. Subject has a history of prior renal artery intervention including balloon\n             angioplasty, stenting or surgery.\n\n          7. Subject had a previous kidney transplant or is a planned recipient of a transplant\n             kidney or is on dialysis.\n\n          8. Subject has a past history of unilateral kidney removal or has a solitary functional\n             kidney for any other reason.\n\n          9. Subject has an estimated glomerular filtration rate (eGFR) of < 45mL/min/1.73m2,\n             using the MDRD formula.\n\n         10. Subject has type 1 diabetes mellitus.\n\n         11. Subject has history of Myocardial Infarction, unstable angina pectoris, or a\n             cerebrovascular accident in the 6 months period prior to enrolment, or documented\n             widespread atherosclerosis, intravascular thrombosis or unstable plaques.\n\n         12. Subject had a significant surgery or cardiovascular intervention in the 6 months\n             period preceding enrollment or is planned to have such a surgery or cardiac\n             intervention in the 6 months period post enrollment.\n\n         13. Subject has hemodynamically significant valvular heart disease for which reduction of\n             blood pressure would be considered hazardous.\n\n         14. Subject is taking systemic steroids or chronic daily NSAIDs.\n\n         15. Subject has a known allergy to Aspirin and/or other procedural drugs or contrast\n             agents which in the investigator's opinion excludes him/her from the study.\n\n         16. Subject has a serious medical condition, which in the opinion of the investigator,\n             may adversely affect the safety and/or effectiveness of the participant or the study\n             (e.g., subjects with active systemic infection, subjects with clinically significant\n             peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as\n             thrombocytopenia, hemophilia, or significant anemia).\n\n         17. Women of childbearing potential with a positive pregnancy test during screening OR\n             women who do not agree to remain on birth control until follow-up at 6 months OR\n             lactating women.\n\n         18. Subject has a known, unresolved history of drug use or alcohol dependency, lacks the\n             ability to comprehend or follow instructions, or would be unlikely or unable to\n             comply with study follow-up requirements.\n\n         19. Subject is currently enrolled in another investigational drug or device trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756300", 
            "org_study_id": "RENABLATE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Resistant Hypertension", 
                "intervention_name": "Renal Sympathetic Denervation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Resistant Hypertension", 
                "intervention_name": "Celsius\u00ae ThermoCool\u00ae RD Multi-electrode Ablation Catheter", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Essential Hypertension", 
            "Renal Denervation", 
            "Vascular Disease", 
            "Renal Catheter Ablation", 
            "Primary Hypertension"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Vikki O'Shea", 
                    "phone": "61 3 9789 0088"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankston", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3199"
                    }, 
                    "name": "Peninsula Heart Centre"
                }, 
                "investigator": {
                    "last_name": "Gregory Szto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "An Roets", 
                    "phone": "+32 (0)3 205 9 305"
                }, 
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }, 
                    "name": "Onze-Lieve-Vrouwziekenhuis Aalst"
                }, 
                "investigator": {
                    "last_name": "E. Wyffels, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nele Peeters", 
                    "phone": "32 89 32 71 93"
                }, 
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }, 
                    "name": "Ziekenhuis Oost-Limburg"
                }, 
                "investigator": {
                    "last_name": "J. Dens, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liz Coling", 
                    "phone": "+420 257 271 111"
                }, 
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "15 030"
                    }, 
                    "name": "Na Homolce Hospital"
                }, 
                "investigator": {
                    "last_name": "Petr Neuzil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martina Striteska, MD", 
                    "phone": "+420 224 96 2605"
                }, 
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "12808"
                    }, 
                    "name": "Charles University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jean-Claude Lubanda, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lars Jorgensen", 
                    "phone": "+45 784 56113"
                }, 
                "facility": {
                    "address": {
                        "city": "Aarhus", 
                        "country": "Denmark", 
                        "zip": "8200"
                    }, 
                    "name": "Aarhus University Hospital, Skejby Sygehus"
                }, 
                "investigator": {
                    "last_name": "A. Kaltoft, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20099"
                    }, 
                    "name": "Asklepios Kliniken, Proresearch St. Georg"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Homburg", 
                        "country": "Germany", 
                        "zip": "66424"
                    }, 
                    "name": "Universitatsklinikum des Saarlandes"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "last_name": "Mario Petruzzi, MD", 
                    "phone": "+39 3474868620"
                }, 
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Generale Regionale"
                }, 
                "investigator": {
                    "last_name": "Massimo Grimaldi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Czech Republic", 
                "Denmark", 
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Multi-center, Non Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02)", 
        "overall_contact": {
            "last_name": "Liesbeth Vanderlinden", 
            "phone": "+32 2 7463527"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: SUKL", 
                "Belgium: AFMPS", 
                "Denmark: Danish Health and Medicines Authority", 
                "Germany: BfArM", 
                "Italy: AIFA", 
                "Australia: Therapeutic Goods Administration (TGA)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety of Renal Denervation in patients with resistant hypertension as measured by Adverse Events [Time Frame:  1, 3, 6 months, annually up to 3 years]", 
            "measure": "Renal Denervation Safety", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Freedom from adverse renal events through 6 months post-procedure.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Reduction of average office based measurements of systolic blood pressure between baseline and 6 months post-procedure.", 
                "measure": "Reduction", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change in 24 hour ambulatory blood pressure measurement (ABPM) from baseline to 3, 6 and 12 months post-procedure.", 
                "measure": "Ambulatory Blood Pressure Change", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 12 months"
            }, 
            {
                "description": "Change in office Systolic (SBP) and Diastolic Blood Pressure (DBP) from baseline to 1, 3, 12, 24, and 36 months post-procedure.", 
                "measure": "Office Blood Pressure Change", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Incidence of subjects achieving target SBP (SBP <140 mmHg, or < 130 for patients with Type II diabetics) at 6 months.", 
                "measure": "Target Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Incidence of changes in medical regimen for high blood pressure and low blood pressure through 6 months post-procedure.\nIncidence of subjects achieving a \u2265 10 mmHg reduction in Systolic Office BP at 1 month, 3 months, 6 months and 12 months post procedure", 
                "measure": "Blood Pressure Changes", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Biosense Webster, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biosense Webster, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}